FMR LLC grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 8.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,525,290 shares of the biopharmaceutical company's stock after acquiring an additional 607,606 shares during the quarter. FMR LLC owned about 9.87% of Xenon Pharmaceuticals worth $294,991,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently modified their holdings of the company. Blue Trust Inc. increased its holdings in Xenon Pharmaceuticals by 140.3% during the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock worth $95,000 after purchasing an additional 1,414 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in Xenon Pharmaceuticals in the 4th quarter valued at $101,000. KBC Group NV lifted its stake in Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after acquiring an additional 780 shares in the last quarter. Magnetar Financial LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth $210,000. Finally, HighMark Wealth Management LLC raised its holdings in shares of Xenon Pharmaceuticals by 22.0% in the fourth quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock valued at $239,000 after purchasing an additional 1,100 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Trading Up 0.4 %
Shares of NASDAQ XENE traded up $0.12 during midday trading on Wednesday, hitting $33.15. The company's stock had a trading volume of 68,970 shares, compared to its average volume of 432,437. The stock has a fifty day moving average price of $35.28 and a 200 day moving average price of $38.91. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -11.76 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05. On average, equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Insider Buying and Selling at Xenon Pharmaceuticals
In related news, CEO Ian Mortimer sold 16,315 shares of the business's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the transaction, the chief executive officer now owns 31,302 shares of the company's stock, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.52% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have commented on XENE. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Royal Bank of Canada restated an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. StockNews.com downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday. HC Wainwright restated a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 target price on the stock. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.38.
Read Our Latest Research Report on XENE
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
